Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.

PURPOSE To evaluate carbonic anhydrase (CA) IX as a surrogate marker of hypoxia and investigate the prognostic significance of different patterns of expression in non-small-cell lung cancer (NSCLC). METHODS Standard immunohistochemical techniques were used to study CA IX expression in 175 resected NSCLC tumors. CA IX expression was determined by Western blotting in A549 cell lines grown under normoxic and hypoxic conditions. Measurements from microvessels to CA IX positivity were obtained. RESULTS CA IX immunostaining was detected in 81.8% of patients. Membranous (m) (P =.005), cytoplasmic (c) (P =.018), and stromal (P <.001) CA IX expression correlated with the extent of tumor necrosis (TN). The mean distance from vascular endothelium to the start of tumor cell positivity was 90 micro m, which equates to an oxygen pressure of 5.77 mmHg. The distance to blood vessels from individual tumor cells or tumor cell clusters was greater if they expressed mCA IX than if they did not (P <.001). Hypoxic exposure of A549 cells for 16 hours enhanced CA IX expression in the nuclear and cytosolic extracts. Perinuclear (p) CA IX (P =.035) was associated with a poor prognosis. In multivariate analysis, pCA IX (P =.004), stage (P =.001), platelet count (P =.011), sex (P =.027), and TN (P =.035) were independent poor prognostic factors. CONCLUSION These results add weight to the contention that mCA IX is a marker of tumor cell hypoxia. The absence of CA IX staining close to microvessels suggests that these vessels are functionally active. pCA IX expression is representative of an aggressive phenotype.

[1]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[2]  J. Folkman,et al.  Vascular injury in transplanted tissues. Fine structural changes in tumor, adult, and embryonic blood vessels. , 1976, Virchows Archiv. B, Cell pathology.

[3]  H. Dienemann,et al.  Importance of microscopic residual disease at the bronchial margin after resection for non-small-cell carcinoma of the lung. , 1992, The Journal of thoracic and cardiovascular surgery.

[4]  S. Pastoreková,et al.  A novel quasi-viral agent, MaTu, is a two-component system. , 1992, Virology.

[5]  B. Teicher,et al.  A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. , 1993, Anticancer Research.

[6]  J. Pastorek,et al.  Expression of MaTu‐MN protein in human tumor cultures and in clinical specimens , 1993, International journal of cancer.

[7]  W. Kao,et al.  Expression of collagen I, smooth muscle alpha-actin, and vimentin during the healing of alkali-burned and lacerated corneas. , 1993, Investigative ophthalmology & visual science.

[8]  J. Minna,et al.  Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. , 1994, Oncogene.

[9]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[10]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[11]  H. Hoffmann,et al.  Inkomplette Resektionen bei Bronchialcarcinom: Morbidität und Prognose , 1997, Der Chirurg.

[12]  J. Pastorek,et al.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. , 1998, The American journal of pathology.

[13]  A S Kennedy,et al.  Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. , 1998, Gynecologic oncology.

[14]  G. Arteel,et al.  Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. , 1999, Radiation research.

[15]  L. Voltolini,et al.  Treatment and survival after lung resection for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  A. Burny,et al.  Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. , 1999, The European respiratory journal.

[17]  M Molls,et al.  Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. , 1999, International journal of radiation oncology, biology, physics.

[18]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[19]  Abdul Waheed,et al.  Nuclear NonO/p54nrb Protein Is a Nonclassical Carbonic Anhydrase* , 2000, The Journal of Biological Chemistry.

[20]  E. Stanbridge,et al.  Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia , 2000, Cancer.

[21]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[22]  S. Leroy,et al.  Temporal trends in survival after surgical resection of localized non-small cell lung cancer. , 2000, Lung cancer.

[23]  K. Haustermans,et al.  Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  R K Jain,et al.  Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. , 2000, Cancer research.

[25]  K. O'Byrne,et al.  Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer , 2000, British Journal of Cancer.

[26]  W. Sly,et al.  Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Supuran,et al.  Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? , 2001, Bioorganic & medicinal chemistry.

[28]  K. O'Byrne,et al.  A biological staging model for operable non-small cell lung cancer , 2001, Thorax.

[29]  A. Harris,et al.  Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. , 2001, Cancer research.

[30]  A. Harris,et al.  Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival , 2001, British Journal of Cancer.

[31]  A. Harris,et al.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Harris,et al.  Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. , 2001, Cancer research.

[33]  K. Yoshikawa,et al.  [The role of MN/CA IX antigen in carcinogenesis and metastasis of renal cell carcinoma]. , 2001, Hinyokika kiyo. Acta urologica Japonica.

[34]  N Zamboglou,et al.  Predictive factors in radiotherapy for non-small cell lung cancer: present status. , 2001, Lung cancer.

[35]  A. Harris,et al.  Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway , 2001, British Journal of Cancer.

[36]  W. Sly,et al.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. , 2001, The American journal of pathology.

[37]  R. Silber,et al.  Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[38]  Donna Richardson,et al.  Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. , 2002, Lung cancer.